Skip to main content
logo
Taysha Gene Therapies logo
Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
3.620
-0.520 (-12.56%)
Oct 13, 2026, 3:51 PM EDT - Market open

Taysha Gene Therapies Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
1,1801,507355331141448
Market Cap Growth
-11.40%324.92%7.14%134.50%-68.52%-55.28%
Enterprise Value
7811,278260227170314
Last Close Price
4.145.501.731.772.2611.65

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
218.31154.1642.5521.4256.40-
PB Ratio
3.486.104.964.42148.704.70
P/TBV Ratio
3.096.104.964.42148.704.70

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
145.62130.8031.1914.6767.98-

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.150.280.880.8263.150.66
Net Debt / Equity Ratio
-1.03-1.01-1.06-1.10-29.45-0.90
Net Debt / EBITDA Ratio
2.622.280.891.180.220.50
Net Debt / FCF Ratio
3.012.660.931.080.260.65
Asset Turnover
0.010.040.050.100.02-
Quick Ratio
17.5312.045.303.921.402.88
Current Ratio
17.7712.235.424.081.543.08
Return on Equity (ROE)
-47.05%-68.45%-121.94%-294.04%-344.67%-100.68%
Return on Assets (ROA)
-23.82%-27.42%-32.51%-29.84%-46.30%-45.80%
Return on Capital Employed (ROCE)
-34.50%-34.90%-64.60%-52.50%-198.50%-106.80%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-12.50%-7.23%-25.19%-33.71%-117.64%-38.94%
FCF Yield
-11.07%-6.23%-23.02%-23.23%-77.25%-29.53%
Buyback Yield / Dilution
-31.09%-27.82%-115.41%-164.20%-16.74%-113.13%
SEC Filings: 10-K · 10-Q